Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art

Case report: Variable response to immunotherapy in ovarian cancer: Our experience within the current state of the art

Despite recent advances in ovarian cancer (OC) treatment, including the introduction of bevacizumab and PARP-inhibitors, OC remains a lethal disease. Other therapeutic options are being explored, such as immunotherapy (IT), which has been proved effective in many solid tumors. Findings about tumor-i...

Full description

Bibliographic Details
Main Authors: Nicoletta Provinciali, Marco Greppi, Silvia Pesce, Mariangela Rutigliani, Irene Maria Briata, Tania Buttiron Webber, Marianna Fava, Andrea DeCensi, Emanuela Marcenaro
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Immunology
Subjects:
ovarian cancer
immunotherapy
avelumab
PD-1
PD-L1
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1094017/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1094017/full

Similar Items